F3 and COVID-19: To illustrate that this is not just a hypothetical risk, peripheral microthrombosis, embolism, and even potential cases of death have already been documented in patients that received infusions of highly TF/CD142-expressing MSCs (67–69), and it is expected that similar cases may arise as a result of MSC infusion in COVID-19.